A Long Look at 274 People Treated for Craniopharyngioma
Original title: Craniopharyngioma Across the Lifespan: A Large Single-Center Cohort Study of Surgical Outcomes, Endocrine Morbidity, and Long-Term Disease Control.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This only looked back at past patient records, not a new treatment.
The short version
Doctors looked back at 274 people with this rare brain tumor to see how they did over time.
What was studied. Doctors reviewed hospital records of 274 people treated for craniopharyngioma at one center. Most tumors, 266 of them, were the adamantinomatous type, and 8 were the papillary type. Ages at diagnosis ran from 1 to 75 years.
What they found. Headache or signs of pressure in the head showed up in 88.0% of people, and vision trouble in 77.4%. Before surgery, 81.5% already had a pituitary gland that was not making enough hormones. After surgery that rose to 98.1%, and 90.1% had trouble holding on to body water right away. Tumor was left behind or grew again in 62.6%, and 32.1% needed more treatment. Thirty-three people died during follow up, and weight gain was common.
What this means, and what it doesn't
What it could mean: This tumor is not cancer, but it can affect health for life. Hormone problems were very common, both before and after surgery. So people with this tumor often need hormone care and checkups for many years. Care from a team of different doctors can help.
What it doesn't mean: This does not mean a new treatment is coming. No drug or new therapy was tested here. Doctors only looked back at records from one hospital, so numbers at other hospitals may differ. It is not proof that one surgery is better than another, and it is not a promise of a cure.
Source: PubMed, August 3, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.